J Appl Biomed 5:57-70, 2007 | DOI: 10.32725/jab.2007.008

Pharmacological aspects of cognitive impairment: past, present and future of drugs in dementia

Kathleen Isensee1, Georg Petroianu2, Holger Stark1,*
1 Johann Wolfgang Goethe-Universität, Institut für Pharmazeutische Chemie, ZAFES/CMP, Frankfurt/Main, Germany
2 United Arab Emirates University, Faculty of Medicine and Health Sciences, Department of Pharmacology and Therapeutics, P.O. Box 17666, Al-Ain, United Arab Emirates

Cognitive impairment is a dramatically increasing problem affecting many individuals as well as the health system. As we have no causal treatment for the loss of memory, symptomatic treatment is needed. Influencing the ACh system is a generally accepted approach, although other therapeutic treatments are in various stages of development. The multiple target drug approach using hybrid compounds may be another optimized move forward for the treatment of cognitive disorders. Since the complex neuronal regulation is slowly being decoded, there is hope that ways will be found to stop neuronal loss and to generate new synapses.

Keywords: cholin esterase inhibitors; NMDA; receptor antagonist; histaminergic neurotransmission; β-amyloid peptide; τ-protein; therapy; animal models; H3 receptor; histamine H3

Received: April 24, 2007; Revised: April 26, 2007; Published: July 31, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Isensee K, Petroianu G, Stark H. Pharmacological aspects of cognitive impairment: past, present and future of drugs in dementia. J Appl Biomed. 2007;5(2):57-70. doi: 10.32725/jab.2007.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Apelt J, Grassmann S, Ligneau X, Pertz HH, Ganellin CR, Arrang JM, Schwartz JC, Schunack W, Stark H: Search for histamine H3 receptor antagonists with combined inhibitory potency at N-methyltransferase: Ether derivatives. Pharmazie 60:79-106, 2005. Go to original source...
    2. Arrang J, Garbarg M, Lancelot J, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC: Highly potent and selective ligands for histamine H3-receptors. Nature 327:117-123, 1987. Go to original source... Go to PubMed...
    3. Bacciottini L, Mannaioni PF, Chiappetta M, Giovannini MG, Blandina P: Acetylcholine release from hippocampus of freely moving rats is modulated by thioperamide and cimetidine. Inflamm. Res. 48:63-64, 1999. Go to original source... Go to PubMed...
    4. Bacciottini L, Giovannelli L, Passani MB, Schunack W, Mannaioni PF, Blandina P: Endogenous histamine in the medial septum-diagonal band complex increases the release of acetylcholine from the hippocampus: A dual-probe microdialysis study in the freely moving rat. Eur. J. Neurosci. 15:1669-1680, 2002. Go to original source... Go to PubMed...
    5. Bamford MJ, Dean DK, Sehmi SS, Wilson DM, Witherington J: Benzodiazepine derivatives for the treatment of neurological disorders. WO 2004/056369, 2004.
    6. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur C, Pudiak CM, Langlois X, Xiao W: Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br. J. Pharmacol. 143:649-661, 2004. Go to original source... Go to PubMed...
    7. Bekkers JM: Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. Science 261:104-106, 1993. Go to original source... Go to PubMed...
    8. Blandina P, Giorgetti M, Bartolini L, Cecchi M, Timmerman H, Leurs R, Pepeu G, Giovannini MG: Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br. J. Pharmacol. 119:1656-1564, 1996. Go to original source... Go to PubMed...
    9. Block W: Galantamine: Revives memory and helps fight Alzheimer's. www.galantamine.cc/articles/galantamine-articles-5.htm (accessed on April 19, 2007).
    10. Bonaventure P, Letavic M, Dugovic C, Wilson S, Aluisio L, Pudiak C, Lord B, Mazur C, Kamme F, Nishino S, Carruthers N, Lovenberg T: Histamine H3 receptor antagonists: From target indentification to drug leads. Biochem. Pharmacol. 73:1084-1096, 2007. Go to original source... Go to PubMed...
    11. Brown RE, Stevens DR, Haas HL: The physiology of brain histamine. Prog. Neurobiol. 63:637-672, 2001. Go to original source... Go to PubMed...
    12. Bullock R: Future directions in the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 13:303-314, 2004. Go to original source... Go to PubMed...
    13. Burns A, O'Brien J: Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. 20:732-755, 2006. Go to original source... Go to PubMed...
    14. Cecchi M, Giorgetti M, Bacciottini L, Giovannini MG, Blandina P: Increase of acetylcholine release from cortex of freely moving rats by administration of histamine into the nucleus basalis magnocellularis. Inflamm. Res. 47:32-33, 1998. Go to original source... Go to PubMed...
    15. Chotard C, Ouimet T, Morisset S, Sahm U, Schwartz JC, Trottier S: Effects of histamine H3 receptor agonist and antagonist on histamine co-transmitter expression in rat brain. J. Neural Transm. 109:293-306, 2002. Go to original source... Go to PubMed...
    16. Cogé F, Guenin SP, Rique H, Boutin JA, Galizzi JP: Structure and expression of the human histamine H4 receptor gene. Biochem. Biophys. Res. Commun. 284: 301-309, 2001. Go to original source... Go to PubMed...
    17. Cowart M, Faghih R, Gfesser G, Curtis M, Pratt JK, Bennani Y, Fox GB, Esbenshade TA, Hancock AA: The medicinal chemistry of novel H3 antagonists. Inflamm. Res. 53:69-70, 2004a. Go to original source... Go to PubMed...
    18. Cowart M, Pratt JK, Stewart AO, Bennani YL, Esbenshade TA, Hancock AA: A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. 14:689-693, 2004b. Go to original source... Go to PubMed...
    19. Cumming P, Vincent SR: Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (Tacrine) and by β-carbolines. Biochem. Pharmacol. 44: 989-992, 1992. Go to original source... Go to PubMed...
    20. Cummings JL: Cholinesterase inhibitors; a new class of psychotropic compounds. Am. J. Psychiatry 157:4-15, 2000. Go to original source... Go to PubMed...
    21. Decker JLM, McGaugh JL: The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory. Synapse 7:151-168, 1991. Go to original source... Go to PubMed...
    22. Delagarza VW: Pharmacologic treatment of Alzheimer's disease: An update. Am. Fam. Physician 68:1365-1372, 2003. Go to PubMed...
    23. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA: Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 305:887-896, 2003. Go to original source... Go to PubMed...
    24. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani Y et al.: Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem. Pharmacol. 68:933-945, 2004. Go to original source... Go to PubMed...
    25. Everitt BJ, Robbins TW: Central cholinergic systems and cognition. Annu. Rev. Psychol. 48:649-684, 1997. Go to original source... Go to PubMed...
    26. Everitt BJ, Robbins TW, Muir JL: Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology (Berl.) 118:82-92, 1995. Go to original source... Go to PubMed...
    27. Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghih R, Hancock AA, Decker MW: Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res. 131:151-161, 2002. Go to original source... Go to PubMed...
    28. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA: Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. 305:897-908, 2003. Go to original source... Go to PubMed...
    29. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cogntion and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 313:176-190, 2005. Go to original source... Go to PubMed...
    30. Ganellin CR, Leurquin F, Piripitsi A, Arrang JM, Garbarg M, Ligneau X, Schunack W, Schwartz JC: Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch. Pharm. 331:395-404: 1998. Go to original source...
    31. Giorgetti M, Bacciottini L, Bianchi L, Giovannini MG, Cecchi M, Blandina P: GABAergic mechanism in histamine H3 receptor inhibition of K+-evoked release of acetylcholine from rat cortex in vivo. Inflamm. Res. 46:33-34, 1997. Go to original source... Go to PubMed...
    32. Giorgetti M, Bacciottini L, Giovannini MG, Colivicchi MA, Goldfarb J, Blandina P.: Local GABAergic modulation of acetylcholine release from the cortex of freely moving rats. Eur. J. Neurosci. 12:1941-1948; 2000. Go to original source... Go to PubMed...
    33. Giovannini MG, Bartolini L, Bacciottini L, Greco L, Blandina P.: Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav. Brain Res. 104:147-155, 1999. Go to original source... Go to PubMed...
    34. Givens B, Sarter M: Modulation of cognitive processes by transsynaptic activation of the basal forebrain. Behav. Brain Res. 84:1-22, 1997. Go to original source... Go to PubMed...
    35. Graßmann S, Apelt J, Sippl W, Ligneau X, Pertz HH, Zhao YH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H: Imidazole derivates as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. Bioorg. Med. Chem. 11:2163-2174, 2003. Go to original source... Go to PubMed...
    36. Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK: Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with Tacrine transaminitis. Br. J. Clin. Pharmacol. 39:411-415, 1995. Go to original source... Go to PubMed...
    37. Hahn B, Shoaib M, Stolerman IP: Nicotine-induced enhancement of attention in the five-choice serial reaction time task: The influence of task demands. Psychopharmacology (Berl.) 162:129-137, 2002. Go to original source... Go to PubMed...
    38. Hancock AA, Fox GB: Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs 13: 1237-1248, 2004. Go to original source... Go to PubMed...
    39. Hancock AA: The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem. Pharmacol. 71:1103-1113, 2006. Go to original source... Go to PubMed...
    40. Holmstedt B: Structure-activity relationship of the organophosphorus anticholinesterase agents. In Koelle GB (ed): Cholinesterases and Anticholinesterase Agents, Berlin, 1963, pp. 429-485. Go to original source...
    41. Hough LB: Genomics meets histamine receptors: New subtypes, new receptors. Mol. Pharmacol. 59:415-419, 2001. Go to original source...
    42. Ireland-Denny L, Parihar AS, Miller TR, Kang CH, Krueger KM, Esbenshade TA, Hancock AA: Species-related pharmacological heterogeneity of histamine H3 receptors. Eur. J. Pharmacol. 433:141-150, 2001. Go to original source... Go to PubMed...
    43. Jann MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20:1-12, 2000. Go to original source... Go to PubMed...
    44. Jia JP, Jia JM, Zhou WD, Xu M, Chu CB, Yan X, Sun YX: Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Chin. Med. J. 117:1161-1164, 2004.
    45. Julian PL, Pikl J: The complete synthesis of Physostigmine (Eserine). J. Am. Chem. Soc. 57:755-757, 1935. Go to original source...
    46. Krall WJ, Sramek JJ, Cutler NR: Cholinesterase inhibitors: A therapeutic strategy for Alzheimer's disease. Ann. Pharmacother. 33: 441-450, 1999. Go to original source... Go to PubMed...
    47. LaBella FS, Queen G, Glavin G, Durant G, Stein D, Brandes LJ: H3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450. Br. J. Pharmacol. 107:161-164, 1992. Go to original source... Go to PubMed...
    48. Lane RM, Potkin SG, Enz A: Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 9: 101-124, 2006. Go to original source... Go to PubMed...
    49. Leurs R, Bakker RA, Timmerman H, de Esch IJ: The histamine H3 receptor: From gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. 4: 107-120, 2005. Go to original source... Go to PubMed...
    50. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J: Neurochemical and behavioral effects of Ciproxifan, a potent histamine H3-receptor antagonist. J. Pharmacol. Exp.Ther. 287:658-666: 1998.
    51. Ligneau X, Morisset S, Tardivel-Lacombe J, Gbahou F, Ganellin CR, Stark H, Schunack W, Schwartz JC, Arrang JM: Distinct pharmacology of rat and human histamine H3 receptors: Role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. 131:1247-1250, 2000. Go to original source... Go to PubMed...
    52. Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD: BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J. Pharmacol. Exp. Ther. 320:365-375, 2007. Go to original source... Go to PubMed...
    53. Lipton SA: Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1:101-110, 2004. Go to original source... Go to PubMed...
    54. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N, Lovenberg TW: Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59:420-426, 2001. Go to original source... Go to PubMed...
    55. Lleo A, Greenberg SM, Growdon JH: Current pharmacotherapy for Alzheimer disease. Annu. Rev. Med. 57:513-533, 2006. Go to original source... Go to PubMed...
    56. Lovenberg TW, Pyati J, Chang H, Wilson SJ, Erlander MG.: Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther. 293:771-778, 2000.
    57. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP et al.: GSK189254 - a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's Disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321:1032-1045, 2007. Go to original source... Go to PubMed...
    58. Meguro KI, Yanai K, Sakai N, Sakurai E, Maeyama K, Sasaki H, Watanabe T: Effects of thioperamide, a histamine H3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol. Biochem. Behav. 50:321-325, 1995. Go to original source... Go to PubMed...
    59. Meier G, Apelt J, Reichert U, Grassmann S, Ligneau X, Elz S, Leurquin F, Ganellin CR, Schwartz JC, Schunack W, Stark H: Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur. J. Pharm. Sci. 13: 249-259, 2001. Go to original source... Go to PubMed...
    60. Melnikova I: Therapies for Alzheimer's disease. Nat. Rev. Drug Discov. 6:341-342, 2007. Go to original source... Go to PubMed...
    61. Mochizuki T, Okakura-Mochizuki K, Horii A, Yamamoto Y, Yamatodani A: Histaminergic modulation of hippocampal acetylcholine release in vivo. J. Neurochem. 62:2275-2282, 1994. Go to original source... Go to PubMed...
    62. Monti JM: Involvement of histamine in the control of the waking state. Life Sci. 53:1331-1338, 1993. Go to original source... Go to PubMed...
    63. Morisset S, Traiffort E, Schwartz JC: Inhibition of histamine versus acetylcholine metabolism as a mechanism of Tacrine activity. Eur. J. Pharmacol. 315:R1-R2, 1996. Go to original source... Go to PubMed...
    64. Morphy R, Kay C, Rankovic Z: From magic bullets to designed multiple ligands. Drug Discov. Today 9:641-651, 2004. Go to original source... Go to PubMed...
    65. Muir JL, Everitt BJ, Robbins TW: AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J. Neurosci. 14: 2313-2326, 1994. Go to original source... Go to PubMed...
    66. Munoz-Torrero D, Camps P: Dimeric and hybrid anti-Alzheimer drug candidates: Curr. Med. Chem. 13:399-422, 2006. Go to original source... Go to PubMed...
    67. Neumann R, Peter HH: Insecticidal organophosphates: Nature made them first. Experientia 43: 1235-1237, 1987. Go to original source...
    68. Orr EL, Quay WB: The effects of castration on histamine levels and 24-hour rhythm in the male rat hypothalamus. Endocrinology 96:941-945, 1984. Go to original source... Go to PubMed...
    69. Ortho-Mcneil neurologics: http://www.rxforsafety.com/news/index.htm (accessed on April 19, 2007).
    70. Panula P, Rinne J, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, Relja M: Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82:993-997, 1997. Go to original source... Go to PubMed...
    71. Passani MB, Blandina P: Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: A parallel story. Methods Find Exp. Clin. Pharmacol. 20: 725-733, 1998. Go to original source... Go to PubMed...
    72. Passani MB, Blandina P: The neuronal histaminergic system in cognition. Curr. Med. Chem. CNS Agents. 4:17-26, 2004. Go to original source...
    73. Passani MB, Cangioli I, Baldi, Bucherelli C, Mannaioni PF, Blandina P: Histamine H3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur. J. Neurosci. 14:1522-1532, 2001. Go to original source... Go to PubMed...
    74. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P: The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. 25:618-625, 2004. Go to original source... Go to PubMed...
    75. Petroianu G, Arafat K, Sasse BC, Stark H: Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie 61:179-182, 2005.
    76. Plaitakis A, Duvoisin RC: Homer's moly identified as Galanthus nivalis L.: Physiologic antidote to Stramonium poisoning. Clin. Neuropharmacol. 6:1-5, 1983. Go to original source... Go to PubMed...
    77. Prast H, Fischer H, Prast M, Philippu A: In vivo modulation of histamine release by autoreceptors and muscarinic acetylcholine receptors in the rat anterior hypothalamus. Naunyn Schmiedebergs Arch. Pharmacol. 350: 599-604, 1994. Go to original source... Go to PubMed...
    78. Prast H, Fischer H, Tran MH, Grass K, Lamberti C, Philippu A: Modulation of acetylcholine release in the ventral striatum by histamine receptors. Inflamm. Res. 46:37-38, 1997. Go to original source... Go to PubMed...
    79. Proudfoot A: The early toxicology of Physiostigmine: A tale of beans, great men and egos. Toxicol. Rev. 25:99-138, 2006. Go to original source... Go to PubMed...
    80. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug. Rev. 9:275-308, 2003. Go to original source... Go to PubMed...
    81. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Drug Discov. Today 3:353-359, 2004. Go to original source... Go to PubMed...
    82. Selbach O, Brown RE, Haas HL: Long-term increase of hippocampal excitability by histamine and cyclic AMP. Neuropharmacology 36:1539-1548, 1997. Go to original source... Go to PubMed...
    83. Schlicker E, Betz R, Göthert M: Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch. Pharmacol. 337:588-590, 1988. Go to original source... Go to PubMed...
    84. Schlicker E, Fink K, Detzner M, Gothert M: Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J. Neural. Transm. 93:1-10, 1993. Go to original source... Go to PubMed...
    85. Schlicker E, Fink K, Hinterhaner M, Gothert M: Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 340: 633-638, 1989. Go to original source... Go to PubMed...
    86. Schlicker E, Werthwein S, Zentner J: Histamine H3 receptor-mediated inhibition of noradrenaline release in the human brain. Fundam. Clin. Pharmacol. 13:120-122, 1999. Go to original source... Go to PubMed...
    87. Stark H: Recent advances in histamine H3/H4 receptor ligands. Expert Opin. Ther. Pat. 13: 851-865, 2004a. Go to original source...
    88. Stark H: Turning from monogamy to strategic promiscuity. Drug Discov. Today 9:736-737, 2004b. Go to original source... Go to PubMed...
    89. Sugimoto H, Ogura H, Arai Y, Iimura Y, Yamanishi: Research and development of Donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 89:7-20, 2002. Go to original source... Go to PubMed...
    90. Summers WK: Tacrine, and Alzheimer's treatments. J. Alzheimers Dis. 9:439-445, 2006. Go to original source... Go to PubMed...
    91. Tedford CE, Hoffmann M, Seyedi N, Maruyama R, Levi R, Yates SL, Ali SM, Phillips JG: High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. Eur. J. Pharmacol. 351: 307-311, 1998. Go to original source... Go to PubMed...
    92. Ting P, Aslanian R, Berlin MY, Boyce CW; Cao J; Mangiaracina P; Mc Cormick KD; Mutahi MW; Rosenblum SB; Shih NY; Solomon DM; Tom WC; Zeng Q: 1-(4-Piperidinyl)benzimidazolones as histamine H3 antagonists. WO-03103669, 2003.
    93. Tuomisto L, Tuomisto J: Diurnal variations in brain and pituitary histamine and histamine-N-methyltransferase in the rat and guinea pig. Med. Biol. 60:204-209, 1982.
    94. Wada H, Inagaki N, Yamatodani A, Watanabe T: Is the histaminergic neuron system a regulatory center for whole-brain activity? Trends Neurosci. 14:415-418, 1991. Go to original source... Go to PubMed...
    95. Wimo A, Winblad B, Aguero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 17:63-67, 2003. Go to original source... Go to PubMed...
    96. Yang R, Hey JA, Aslanian R, Rizzo CA: Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 66:128-135, 2002. Go to original source... Go to PubMed...
    97. Yao BB, Hutchins CW, Carr TL, Cassar S, Masters JN, Bennani YL, Esbenshade TA, Hancock AA: Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity. Neuropharmacology 44:773-786, 2003. Go to original source... Go to PubMed...

    Return to the content